格卡瑞韋/哌侖他韋

格卡瑞韋/哌侖他韋
組成
[[格卡瑞韋（英語：Glecaprevir）]]	NS3/NS4A（英語：Hepatitis C virus nonstructural protein 4A）抑制劑
[[哌侖他韋（英語：pibrentasvir）]]	NS5A（英語：Hepatitis C virus nonstructural protein 5A）抑制劑
臨床資料
商品名（英語：Drug nomenclature）	Mavyret, Maviret, others
AHFS/Drugs.com	Monograph
MedlinePlus	a617039
核准狀況	美 DailyMed: and pibrentasvir Glecaprevir and pibrentasvir;
懷孕分級	澳: B1 ; ;
給藥途徑	口服給藥
ATC碼	J05AP57 (WHO) ;
法律規範狀態
法律規範	澳：限醫生處方（S4）; 加：處方藥（℞-only）; 歐：Rx-only; 英：處方藥（℞-only） (POM); 美：處方藥（℞-only）; 處方藥（℞-only）;
識別資訊
KEGG	D11014;

格卡瑞韋/哌侖他韋（Glecaprevir/pibrentasvir， G/P）是一種用於治療丙型肝炎的複方藥^[4]。內含格卡瑞韋（英語：Glecaprevir）和哌侖他韋（英語：pibrentasvir）^[5]。對丙型肝炎的六型病毒皆有效^[4]。治療十二週後，81% 至 100% 的患者體內未再檢出丙型肝炎病毒^[6]。此藥物需每日口服一次，隨餐服用^[4]。

最常見的副作用包括頭痛、腹瀉和疲勞^[6] ^[7]。對於患有乙型肝炎的患者，可能會發生病毒再活化^[7]。中度至重度肝病患者不建議使用此藥物^[6]。格卡瑞韋會阻斷丙型肝炎病毒非結構蛋白3（NS3）/4A（英語：Hepatitis C virus nonstructural protein 4A）蛋白酶，而哌侖他韋則會阻斷非結構蛋白5A（英語：Hepatitis C virus nonstructural protein 5A）^[4]。

格卡瑞韋/哌侖他韋於 2017 年在美國和歐洲取得醫療使用許可^[5] ^[4]。名列世界衛生組織基本藥物標準清單^[8]。

參考文件

^ Glecaprevir / pibrentasvir (Mavyret) Use During Pregnancy. Drugs.com. 10 October 2019 [30 March 2020].
^ Liver disease. Health Canada. 9 May 2018 [13 April 2024].
^ Maviret 100 mg/40 mg Film-coated Tablets - Summary of Product Characteristics (SmPC). (emc). 11 March 2020 [30 March 2020].
^ ^4.0 ^4.1 ^4.2 ^4.3 ^4.4 Maviret EPAR. European Medicines Agency (EMA). 17 August 2017 [30 March 2020]. （原始內容存檔於30 December 2019）.
^ ^5.0 ^5.1 FDA approves Mavyret for Hepatitis C (新聞稿). U.S. Food and Drug Administration (FDA). 3 August 2017 [30 March 2020]. （原始內容存檔於30 March 2020）.
^ ^6.0 ^6.1 ^6.2 FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to eight weeks. U.S. Food and Drug Administration (FDA). 26 September 2019 [1 October 2019]. （原始內容存檔於27 September 2019）.
^ ^7.0 ^7.1 British national formulary : BNF 76 76. Pharmaceutical Press. 2018: 620. ISBN 9780857113382.
^ World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[Drugs.com_pregnancy-1] Glecaprevir / pibrentasvir (Mavyret) Use During Pregnancy. Drugs.com. 10 October 2019 [30 March 2020].

[2] Liver disease. Health Canada. 9 May 2018 [13 April 2024].

[3] Maviret 100 mg/40 mg Film-coated Tablets - Summary of Product Characteristics (SmPC). (emc). 11 March 2020 [30 March 2020].

[EMA2017-4] 4.0 ^4.1 ^4.2 ^4.3 ^4.4 Maviret EPAR. European Medicines Agency (EMA). 17 August 2017 [30 March 2020]. （原始內容存檔於30 December 2019）.

[FDA2017-5] 5.0 ^5.1 FDA approves Mavyret for Hepatitis C (新聞稿). U.S. Food and Drug Administration (FDA). 3 August 2017 [30 March 2020]. （原始內容存檔於30 March 2020）.

[FDA2019-6] 6.0 ^6.1 ^6.2 FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to eight weeks. U.S. Food and Drug Administration (FDA). 26 September 2019 [1 October 2019]. （原始內容存檔於27 September 2019）.

[BNF76-7] 7.0 ^7.1 British national formulary : BNF 76 76. Pharmaceutical Press. 2018: 620. ISBN 9780857113382.

[WHO21st-8] World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]